Sydney, Australia 30 July 2019 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce the appointment of Robert Vickery as Chief Financial Officer.
Robert is a transaction and change focused finance executive with over 30 years of experience and extensive involvement in life sciences and early stage businesses. Robert joins Clarity from Viralytics, an ASX listed biotechnology company acquired by Merck & Co for AUD$502 million in 2018, which was the largest transaction in the Australian biotech sector for an R&D stage company. Robert led the finance function at Viralytics for over 6 years and was a key member of the due diligence target team during the trade sale negotiations and due diligence process with Merck, liaising with legal and investment banking teams, as well as leading the finance, IT and HR integration efforts post acquisition.
Robert commented on his appointment: “I am delighted to be joining Clarity as CFO at this exciting time and to continue my passion for start-ups and biotech in this role. I am pleased to be joining the team of highly driven and switched-on individuals and working together on advancing such internal corporate processes as accounting, auditing, HR and IT. I am also looking forward to leveraging my experience of the capital markets and supporting Clarity’s Executive Team in executing strategic transactions.”
Clarity’s Executive Chairman Dr Alan Taylor said: “We are excited to welcome Robert to our team and are looking forward to working together on enhancing such key corporate functions as finance, IT and HR at Clarity. Robert joins the team at a time of strong corporate growth and clinical development and his hands-on experience in the finance department of an ASX listed biotech, along with his involvement in mergers and acquisitions including integration efforts during the Merck acquisition, will be invaluable for preparing Clarity for any potential transactions that might arise in the future.”
Robert holds a Bachelor of Commerce from the University of New South Wales and is an Associate of the Institute of Chartered Accountants (CA) and the Governance Institute of Australia (GIA).
Media Contact
Dr Alan Taylor
Executive Chairman
Ph: +61 (0)413 871 165
E: ataylor@claritypharm.com
About Clarity
Clarity is a personalised medicine company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing targeted therapies for the treatment of cancer and other serious diseases in adults and children.
